ArticlePediatric cardiology2026
Comparison of Heparin-Based Anticoagulation in Patients With and Without High Output Chylothorax: A Pilot Study.
Article in Pediatric cardiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In infants and children with chylothorax after cardiac surgery, loss of antithrombin (AT) may impair the therapeutic effect of AT-dependent anticoagulants such as unfractionated heparin (UFH) and low molecular weight heparin (LMWH). This retrospective pilot study included patients 0-18 years receiving a therapeutic course of UFH or enoxaparin, excluding those on mechanical circulatory support or renal replacement. High output chylothorax courses were matched 1:2 to controls by age and anticoagulation duration. Therapeutic attainment and adverse events were compared for each agent. This study included 16 UFH and 17 enoxaparin courses plus matched controls. Among UFH courses, high output chylothorax was associated with a numerically lower percentage of therapeutic anti-Xa levels during the first seven days (55.9% vs. 68.8%, p = 0.06). Though no differences were observed for dose at first therapeutic level, chylothorax courses required numerically more dose adjustments to reach first therapeutic level and a greater proportion received AT repletion. Among enoxaparin courses, no significant difference was observed for time to therapeutic anti-Xa, though chylothorax courses required numerically higher doses and more dose adjustments to reach first therapeutic level. Baseline and minimum AT were lower in the chylothorax group for both agents. No differences were found in the incidence of thrombosis or bleeding. High output chylothorax after cardiac surgery may impair the therapeutic effect of UFH, while the effect on enoxaparin is less clear. Though most differences were nonsignificant, the findings suggest larger studies are needed to assess the impact of chylothorax on hemostatic outcomes.
Indexed as
Identifiers
41273422What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.